SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as traders discuss a potential short squeeze, fueled by positive financial performance and increasing user engagement; some highlight Lunate Capital's significant investment as a sign of institutional confidence. The community is weighing the potential for a gamma squeeze against concerns about its China ties and overall market volatility. Some investors are drawing comparisons to other high-growth platforms like $HOOD and $SOFI, while others are setting ambitious price targets for 2025 and beyond.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending amid mixed sentiment following earnings, with some emphasizing the company's pivot to AI and HPC and its growth potential, while others highlight missed estimates and debt concerns. Community discussions revolve around analyst price targets, potential short squeezes, and the impact of Bitcoin's price movements on the stock. Some traders are expressing frustration with the stock's volatility, while others remain optimistic about its long-term prospects in the AI and data center space.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending as investors discuss its pivot to the defense sector and the potential acquisition of Star 26 Capital, particularly Rimon and its Iron Dome technology. While some express optimism about defense spending tailwinds and a possible short squeeze, others are wary of potential share dilution and the company's execution capabilities. The community is closely watching for news regarding the Star 26 acquisition vote and updates on the company's strategic direction.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending as investors discuss its potential in the AI server market, fueled by record AI server orders and increasing momentum. Community members debate whether the company's financial performance justifies the recent stock movement, while analysts update their ratings and price targets. Some are comparing Dell with competitors like Supermicro in the context of Google's TPU strategy.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as enthusiasm builds around its AI capabilities with Gemini 3, potentially challenging NVDA's dominance in the AI chip market. Community members are discussing the implications of Meta potentially using Google's TPUs, viewing it as a positive catalyst for GOOGL while some analysts believe that the AI infrastructure market is large enough for both companies to succeed. Some investors are noting Google's potential to reach a $4 trillion market cap and the company's robust position in the AI landscape.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as traders discuss its potential in the prediction markets following news of a joint venture with Susquehanna. The community is weighing the stock's connection to crypto and debating whether it can decouple and sustain its upward momentum. Bullish sentiment is fueled by the company's move to build a dedicated futures and derivatives exchange, while some traders express concern about recent price volatility.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as the community discusses its recent downturn, with some viewing it as a buying opportunity, while others express concern over debt and AI strategy. Talk surrounds analyst ratings, potential for a short squeeze, and the impact of AI developments on Oracle's future. Community members are closely watching key support and resistance levels.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as the community debates the impact of increased competition, particularly from Google's TPUs and Meta's exploration of alternative AI chips, on its market dominance and future growth. Despite concerns about market saturation and potential shifts in the AI landscape, some analysts and investors are highlighting NVIDIA's strong fundamentals, leading market position, and potential for continued growth amid a broader AI expansion. Discussions also involve contrasting viewpoints on the stock's valuation and potential influence of external factors, including analyst ratings and geopolitical developments.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler ($ZS) is trending following its earnings report, with community discussions focusing on whether the company's raised guidance justifies its valuation. While some investors express concerns about profitability and await upgrades, others see the dip as a buying opportunity, pointing to strong revenue growth and potential for a rebound in the cybersecurity sector. Upgrades from several analysts are also driving interest in the stock.

Nutanix, Inc. engages in the provision of a cloud platform leveraging web-scale engineering and consumer-grade design. It operates through the following geographic segments: United States, Europe, the Middle East, Africa, Asia Pacific, and Other Americas. The firm also provides software solutions and cloud services to customers' enterprise infrastructure. The company was founded by Dheeraj Pandey, Ajeet Singh, and Mohit Aron in 2009 and is headquartered in San Jose, CA.

Nutanix Inc - Ordinary Shares - Class A

Nutanix Inc 

Nutanix is trending due to recent earnings and revenue results, sparking mixed community sentiment. While some investors are optimistic about the company's growth potential and strategic partnerships, others express concerns about guidance and market dynamics. Discussions also revolve around potential price targets and the stock's overall valuation within the cloud computing sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%

Shkreli said that the company’s only asset, Dermiocel, will not yield positive results in the HOPE-3 study.

Equity

Shkreli said that the company’s only asset, Dermiocel, will not yield positive results in the HOPE-3 study.


What is B. Riley's Forecast for CAPR FY2025 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities research analysts at B. Riley lowered their FY2025 earnings estimates for shares of Capricor Therapeutics in a research report...

What is Roth Capital's Estimate for CAPR FY2025 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Stock analysts at Roth Capital upped their FY2025 earnings per share estimates for shares of Capricor Therapeutics in a research note issued...

B. Riley Research Analysts Cut Earnings Estimates for CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities research analysts at B. Riley cut their FY2026 EPS estimates for shares of Capricor Therapeutics in a research note issued to...

CAPR FY2025 EPS Estimate Boosted by Cantor Fitzgerald

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Capricor Therapeutics in a research report issued...

HC Wainwright Has Positive Estimate for CAPR FY2025 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Capricor Therapeutics in a research...

Investors Purchase High Volume of Capricor Therapeutics Put Options (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors purchased 17,427 put options on the company. This is an...

Capricor Therapeutics (NASDAQ:CAPR) Issues Earnings Results

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.54) earnings per share for the quarter, meeting...

<ul class="summary-bullets"><li>Capricor plans to resubmit its Duchenne therapy application in 2026 with new cardiac efficacy data.</li><li>FDA signaled flexibility that could speed approval if results are strong.</li><li>Retail traders called the company’s RMAT status a potential “secret weapon.”</li></ul>Capricor Therapeutics shares rose over 3% in after-hours trading after the company said during its third-quarter conference call that it is rebuilding its approval bid for its Duchenne muscular dystrophy therapy, deramiocel, following an FDA rejection that requested additional safety, efficacy, and manufacturing data.The company said it plans to resubmit its Biologics License Application (BLA) in 2026, after the FDA indicated it would review the totality of data from its study rather than rely solely on skeletal muscle endpoints. The approach allows Capricor to highlight cardiac efficacy, a key determinant of disease progression in Duchenne-associated cardiomyopathy.<h2 class="st-heading-2">FDA Meeting Opens Door To Flexible Review</h2>While the Complete Response Letter (CRL) issued in July was unexpected, Capricor said on the call that Capricor was “well-positioned” to respond using data from its ongoing late-stage clinical trial, which is expected to report results within weeks.During an FDA Type A meeting in August, the agency said those trial results could be used to address the issues cited in the CRL. Capricor also asked the FDA to keep its current BLA open and maintain the indication for Duchenne-associated cardiomyopathy.To advance that path, Capricor proposed designating left ventricular ejection fraction (LVEF), a cardiac function measure, as the primary efficacy endpoint. While the FDA did not allow the formal change, it agreed to exercise regulatory flexibility in reviewing the data, indicating that strong cardiac results could support approval.<h2 class="st-heading-2">Manufacturing Update</h2>Capricor said its San Diego GMP facility, which produces the commercial-scale version of deramiocel, has passed its pre-license inspection (PLI) and that all chemistry, manufacturing, and controls (CMC) concerns noted in the CRL have been resolved.The company plans a Type 2 resubmission, triggering a six-month FDA review window, and said a strong efficacy signal could accelerate approval as early as 2026.If approved before Sept. 30, 2026, Capricor would qualify for a Priority Review Voucher (PRV) under its Rare Pediatric Disease Designation, potentially adding non-dilutive value. The company ended the third quarter with $98.6 million in cash, providing runway into late 2026, and remains eligible for an $80 million milestone from NS Pharma upon approval.<h2 class="st-heading-2">Stocktwits Traders Call RMAT Capricor’s ‘Secret Weapon’</h2>On Stocktwits, retail sentiment for Capricor was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/capr_stock_jpg_674aa0a57c.webp" alt="capr stock.jpg" width="969" height="139"><figcaption>CAPR sentiment and message volume as of November 10 | Source: Stocktwits</figcaption></figure>Some users pointed to Capricor’s Regenerative Medicine Advanced Therapy (RMAT) designation as a potential catalyst. One user said the RMAT pathway was the company’s “secret weapon,” noting that Duchenne’s fatal nature and unmet medical need could allow the FDA to grant accelerated approval based on surrogate endpoints such as cardiac function improvements rather than long-term survival data.<stembedurl>https://stocktwits.com/WBinthehouse/message/635689643</stembedurl>Another user said the “best takeaway” from Capricor’s earnings call was the expectation of a “surprise data drop” within one to three weeks, adding that they were optimistic about positive top-line results from the study.<stembedurl>https://stocktwits.com/Bentradez/message/635689357</stembedurl>A third user said the FDA’s stated willingness to show flexibility could let Capricor “turn on the RMAT cheat code,” meaning the company could leverage its designation to pursue accelerated approval if left ventricular ejection fraction (LVEF) data are strong even when skeletal endpoints fall slightly short. The user described this as a potential “fallback” that could bring deramiocel to market months faster.<stembedurl>https://stocktwits.com/WBinthehouse/message/635687964</stembedurl><a href="https://stocktwits.com/symbol/CAPR">Capricor’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection

Capricor plans to resubmit its Duchenne therapy application in 2026 with new cardiac efficacy data.

Preview: Capricor Therapeutics's Earnings

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

$NVDA

$AAPL

$GOOG/$GOOGL

$MSFT

Which company ends 2025 with the largest market cap?

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc